09Oct

Strategic Partnership for New Bladder Cancer Diagnostic Test in the UK

Alpha Laboratories Ltd. (Eastleigh, UK) is delighted to have been appointed as the exclusive distributor for Arquer Diagnostics Ltd (“Arquer”) in the UK and Republic of Ireland. Arquer (Sunderland, UK) is an in-vitro diagnostic company developing breakthrough diagnostic tests for the detection of bladder and prostate cancer. Its non-invasive cancer diagnostic tests are based on the MCM5 (minichromosome maintenance protein) platform. The first Arquer product is ADXBLADDER, a bladder cancer diagnostic test, and a number of clinical trials are running to validate many other indications. 

Michelle Holland, Alpha Laboratories’ Diagnostics Sales and Marketing director says, “Arquer shares the Alpha Laboratories’ vision to provide innovative diagnostic pathways that enhance patient care and improve outcomes, whilst reducing overall healthcare costs. We welcome this partnership to expand our specialist diagnostics portfolio into this important clinical area.

One of the key elements of the success of any product launch is the quality of the technical and scientific support delivered to all stakeholders. I am extremely excited about the partnership with Alpha Laboratories, as they have an incredible track record of success and a reputation in the IVD field. The Arquer Diagnostics’ Team and I look forward to many years of success together with Alpha Laboratories”, says Nadia Whittley, Arquer CEO.

For further information please contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk 

Related

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >

New Blood Collection Tubes Stabilise Nucleated Blood Cells

The new Streck Cell-Free DNA BCT® CE blood collection tubes, now available in the UK from Alpha Labo...

Read More >

RPS Diagnostics partners with Atomo Diagnostics to develop next generation Febridx blood tests for Antibiotic Stewardship in the Outpatient setting

Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, ...

Read More >

OGT launches enhanced SureSeq™ Interpret NGS analysis software

Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data

Read More >

Evaluation studies confirm improved oncology patient pathways through HORIBA Medical’s new POC haematology analyser

Yumizen H500 full blood count analyser demonstrates exceptional correlation with larger laboratory-b...

Read More >